Climaxol regularly appears in searches related to weight loss. This herbal medicine, registered in France for venous circulation disorders, has no official indication related to slimming. What do its composition, regulatory status, and available data really say about any potential effect on weight?
Climaxol and weight loss: what the regulatory status says
Climaxol is a liquid solution in drops registered as a traditional herbal medicine. Its indication concerns venous circulation disorders, particularly heavy legs and hemorrhoids. The National Agency for the Safety of Medicines and Health Products (ANSM) classifies it in this category, not among treatments for obesity or overweight.
Recommended read : 2024 Fashion Trends: Inspirations and Tips for a Unique and Bold Style
The Transparency Commission has reassessed its Medical Service Rendered (SMR) and deemed it “insufficient” in its current indication. This evaluation means that, even for venous disorders, the recognized medical interest remains limited. A diverted use for weight loss would therefore fall outside any scientific or regulatory basis.
For those looking for an opinion on Climaxol for weight loss, the conclusion is the same: no published study documents an effect of this product on body weight.
See also : How to Succeed in Your Real Estate Project: Tips and Trends for Smart Investing
Composition of Climaxol compared to recognized weight management actives
The composition of Climaxol is based on three herbal tinctures. None of these plants are among the actives studied for their effects on metabolism or satiety.
| Component | Origin | Documented indication | Effect on weight |
|---|---|---|---|
| Witch hazel | Leaf and bark tincture | Venous circulation | None documented |
| Butcher’s broom (Ruscus aculeatus) | Rhizome tincture | Heavy legs, hemorrhoids | None documented |
| Horse chestnut | Fruit tincture | Venous insufficiency | None documented |
| Orlistat (comparison) | Synthetic molecule | Obesity (MA) | Reduction of fat absorption |
| Liraglutide (comparison) | GLP-1 analogue | Obesity (MA) | Appetite regulation |
The three plants in Climaxol act on venous tone. The solvent used is 65% ethanol, which represents a significant alcohol content for daily intake in drops.
In contrast, medications that have market authorization for weight loss (orlistat, liraglutide, naltrexone/bupropion combination) target specific mechanisms: fat transformation, appetite regulation, or reduction of intake amounts. Climaxol does not target any of these mechanisms.
Venotonic products and slimming promises: a common amalgam
The association between circulation products and slimming claims is not unique to Climaxol. It is based on a shortcut: water retention worsening the sensation of swollen legs, some consumers interpret an improvement in venous comfort as weight loss.
Independent analyses of new so-called “slimming” dosage forms (shots, gummies, patches) show that, in the few available trials, weight loss generally does not exceed one to two kilograms over several weeks, with no significant difference from a placebo in most cases.
Several factors contribute to this amalgam:
- The temporary reduction of water retention, perceived as slimming but without actual fat loss
- The marketing of certain dietary supplements that combine “drainage” and “slimming” without clear distinction
- The lack of strict control over claims of products sold without prescription, unlike medications subject to MA
Climaxol, as a registered medicine (and not a dietary supplement), does not carry any slimming claims on its packaging. Its use for weight loss is considered off-label, without medical supervision or proof of efficacy.
Authorized medications for weight loss: criteria and limits
Medications for obesity authorized in France meet strict criteria. They are prescribed under medical supervision, generally for patients whose body mass index exceeds a defined threshold, and in conjunction with a diet and physical activity.
- Orlistat partially blocks the intestinal absorption of dietary fats
- Liraglutide, a GLP-1 analogue, acts on satiety centers
- The naltrexone/bupropion combination acts on brain circuits related to food intake
- Semaglutide represents a more recent prospect in this same therapeutic class
These molecules have undergone controlled clinical trials before obtaining their authorization. No venotonic has ever passed these stages for a weight indication.
In contrast, Climaxol does not require a prescription and remains available in pharmacies. This accessibility may give the impression that it is a harmless product, but the presence of alcohol in its formulation and the lack of data on prolonged off-label use call for caution.
Side effects and precautions with Climaxol
The product characteristics summary mentions that clinical data remain limited. The 65% ethanol used as a solvent raises questions about tolerance in certain profiles: pregnant women, individuals under liver treatment, former alcohol-dependent consumers.
In the absence of sufficient data on the safety of off-label use for weight loss, consulting a doctor or pharmacist remains the only reasonable step before any off-label use. The SMR deemed insufficient by the Transparency Commission reinforces this conclusion: even in its primary indication, the clinical benefit is not solidly established.
Climaxol remains a herbal medicine intended for venous comfort, not a weight management tool. The regulatory data, composition, and total lack of studies on weight loss converge towards the same conclusion: seeking a slimming effect in this product amounts to attributing properties it does not have.